Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value

*Lanzhou University Second College of Clinical Medicine, Lanzhou University, Lanzhou, China; and

†Department of Cardiology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.

Correspondence: Xiaowei Zhang, MD, PhD, Department of Cardiology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou 730000, China (e-mail: [email protected]).

Supported by the National Natural Science Foundation of China (NSFC 82060080), Gansu science and Technology Department Project (20YF3WA016), Gansu Provincial Department of education project (2020B-024), Project of Lanzhou Science and Technology Bureau (2019-RC36), and the Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital (CY2019-MS15). This study was also supported by the Gansu heart rehabilitation engineering research center (CRQI-C00535).

The authors report no conflicts of interest.

Y. Xie and Y. Wei contributed equally to this work.

Study concept and design: X. Zhang; Drafting of the manuscript: Y. Xie and Y. Wei; Critical revision of the manuscript for important intellectual content: D. Li, J. Pu, and H. Ding. All authors read and approved the final manuscript.

留言 (0)

沒有登入
gif